Home/Filings/4/0001578563-22-000006
4//SEC Filing

Sullivan Christopher Ryan 4

Accession 0001578563-22-000006

CIK 0001534120other

Filed

Mar 9, 7:00 PM ET

Accepted

Mar 10, 5:50 PM ET

Size

7.9 KB

Accession

0001578563-22-000006

Insider Transaction Report

Form 4
Period: 2022-03-08
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-03-08+400,000400,000 total
    Exercise: $0.70Exp: 2032-03-08Common Stock (400,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2022-03-08+50,00050,000 total
    Exercise: $0.70Exp: 2032-03-08Common Stock (50,000 underlying)
Footnotes (2)
  • [F1]One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date.
  • [F2]The stock option will vest in full on March 8, 2023, subject to the Reporting Person's continued service through the vesting date.

Issuer

Avalo Therapeutics, Inc.

CIK 0001534120

Entity typeother

Related Parties

1
  • filerCIK 0001810417

Filing Metadata

Form type
4
Filed
Mar 9, 7:00 PM ET
Accepted
Mar 10, 5:50 PM ET
Size
7.9 KB